Latest news with #ChengYing
The Star
13-07-2025
- Health
- The Star
Top Chinese oncologist and director of Jilin Cancer Hospital, Cheng Ying, has passed away
A top Chinese oncologist and physician-scientist, Cheng Ying, has died suddenly aged 62, according to multiple sources. There has been no official statement about the doctor's death, and the cause of death is not known. Cheng was director of the Jilin Cancer Hospital and according to their outpatient records, she last appeared at the specialist team clinic she led on the morning of July 2. Subsequently, her appointment schedule was removed from the hospital's outpatient information sheet, and news about her from the past year has been removed from the hospital's website. The most recent publicly documented appearance by Cheng was on May 10 at the annual meeting of the small-cell carcinoma committee of the Chinese Anti-Cancer Association in Changchun. Cheng served as chairwoman of the committee at the meeting, where she presented and released a report on research into small-cell carcinoma. Cheng was a top-tier cancer expert in China. In July 1986, she graduated from Bethune Medical University, now called the School of Medicine, Jilin University. She then held positions including director, deputy president, president and party secretary at Jilin Cancer Hospital. In 2009, she received the Chinese medical profession's highest honour, the Chinese Physician Award, and in 2014, was named Outstanding Hospital President by the Chinese Hospital Association. Cheng was a pioneer in clinical trials for tumour diseases, especially small-cell lung carcinoma. From 2018, she ranked first nationally for seven consecutive years in the number of newly initiated registration clinical trials. The 2019 China Principal Investigator Tumor Clinical Trial Undertaking Report ranked Cheng No 1 nationally across multiple statistical dimensions. On September 13 last year, results from the ADRIATIC clinical study led by Cheng as principal investigator were published in The New England Journal of Medicine, an esteemed international medical journal. The study, funded by AstraZeneca, showed that patients with small-cell carcinoma who received adjuvant duvalizumab – a type of therapy involving the immunotherapy drug durvalumab given after primary treatment – had significantly longer overall and progression-free survival than those who received placebo. Duvalizumab, a PD-L1 immunosuppressant, was approved in China in December 2019 for the treatment of non-small-cell lung carcinoma patients and has since been expanded for the treatment of small-cell carcinoma, either as a single agent or in combination. In October, AstraZeneca revealed that its global executive vice-president international and president of AstraZeneca China, Lei Wang, was under investigation by Chinese authorities. In January, a letter of opinion issued by Shenzhen Customs indicated that AstraZeneca was suspected of evading import taxes on duvalizumab worth US$900,000. AstraZeneca said it 'declined to comment'. There has been no official statement on Cheng's death from either Changchun city authorities or the Jilin Cancer Hospital. Top hospital directors in China hold power and influence but have also borne the pressure of rapid growth in the medical and health sectors in recent years. In 2016, Shi Yingkang was the longest-serving president in the history of West China Hospital, having led the top-tier Chinese hospital for 20 years, when he died suddenly. The Chinese government has targeted the sector as part of an anti-corruption campaign. By August 2023, investigators reported netting more than 160 hospital bosses that year alone. - SOUTH CHINA MORNING POST
South China Morning Post
09-07-2025
- Health
- South China Morning Post
Cheng Ying, Jilin Cancer Hospital director and AstraZeneca-funded scientist, dies suddenly
A top Chinese oncologist and physician-scientist, Cheng Ying, has died suddenly aged 62, according to multiple sources. There has been no official statement about the doctor's death, and the cause of death is not known. Cheng was director of the Jilin Cancer Hospital and according to their outpatient records, she last appeared at the specialist team clinic she led on the morning of July 2. Subsequently, her appointment schedule was removed from the hospital's outpatient information sheet, and news about her from the past year has been removed from the hospital's website. 10:51 New oral treatment for blood cancer offers 97% cure rate, Hong Kong researchers say New oral treatment for blood cancer offers 97% cure rate, Hong Kong researchers say The most recent publicly documented appearance by Cheng was on May 10 at the annual meeting of the small-cell carcinoma committee of the Chinese Anti-Cancer Association in Changchun. Cheng served as chairwoman of the committee at the meeting, where she presented and released a report on research into small-cell carcinoma. Cheng was a top-tier cancer expert in China. In July 1986, she graduated from Bethune Medical University, now called the School of Medicine, Jilin University. She then held positions including director, deputy president, president and party secretary at Jilin Cancer Hospital. In 2009, she received the Chinese medical profession's highest honour, the Chinese Physician Award, and in 2014, was named Outstanding Hospital President by the Chinese Hospital Association.
